DE60327994D1 - Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften - Google Patents
Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaftenInfo
- Publication number
- DE60327994D1 DE60327994D1 DE60327994T DE60327994T DE60327994D1 DE 60327994 D1 DE60327994 D1 DE 60327994D1 DE 60327994 T DE60327994 T DE 60327994T DE 60327994 T DE60327994 T DE 60327994T DE 60327994 D1 DE60327994 D1 DE 60327994D1
- Authority
- DE
- Germany
- Prior art keywords
- ansamycine
- biological properties
- improved pharmacological
- ansamycins
- dimers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000000144 pharmacologic effect Effects 0.000 title 1
- 239000013011 aqueous formulation Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000539 dimer Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 238000009877 rendering Methods 0.000 abstract 1
- 230000003381 solubilizing effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/5532—Seven-(or more) membered rings
- C07F9/5535—Seven-(or more) membered rings condensed with carbocyclic rings or ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35527502P | 2002-02-08 | 2002-02-08 | |
US36705502P | 2002-03-22 | 2002-03-22 | |
PCT/US2002/039993 WO2003050295A2 (en) | 2001-12-12 | 2002-12-12 | Assays and implements for determining and modulating hsp90 binding activity |
PCT/US2003/004283 WO2003066005A2 (en) | 2002-02-08 | 2003-02-10 | Ansamycins having improved pharmacological and biological properties |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60327994D1 true DE60327994D1 (de) | 2009-07-30 |
Family
ID=40794734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60327994T Expired - Lifetime DE60327994D1 (de) | 2002-02-08 | 2003-02-10 | Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften |
Country Status (8)
Country | Link |
---|---|
US (1) | US7465718B2 (de) |
EP (1) | EP1472230B1 (de) |
JP (1) | JP2005530689A (de) |
AT (1) | ATE433961T1 (de) |
AU (1) | AU2003217393B8 (de) |
CA (1) | CA2474508A1 (de) |
DE (1) | DE60327994D1 (de) |
WO (1) | WO2003066005A2 (de) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6872715B2 (en) | 2001-08-06 | 2005-03-29 | Kosan Biosciences, Inc. | Benzoquinone ansamycins |
DE60327994D1 (de) | 2002-02-08 | 2009-07-30 | Conforma Therapeutics Corp | Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften |
US20060014730A1 (en) * | 2002-04-10 | 2006-01-19 | Conforma Therapeutics Corporation | Ansamycin formulations and methods for producing and using same |
WO2003091264A2 (en) | 2002-04-26 | 2003-11-06 | Gilead Sciences, Inc. | Non nucleoside reverse transcriptase inhibitors |
WO2005002626A2 (en) | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
WO2004096285A2 (en) * | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Anti-infective phosphonate conjugates |
EA200501676A1 (ru) | 2003-04-25 | 2006-04-28 | Джилид Сайэнс, Инк. | Фосфонатсодержащие ингибиторы киназы (варианты), способ их получения, фармацевтическая композиция, лекарственная форма на их основе и способ ингибирования киназы у млекопитающего (варианты) |
WO2004096287A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds |
US7432261B2 (en) | 2003-04-25 | 2008-10-07 | Gilead Sciences, Inc. | Anti-inflammatory phosphonate compounds |
US7407965B2 (en) | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
US7470724B2 (en) | 2003-04-25 | 2008-12-30 | Gilead Sciences, Inc. | Phosphonate compounds having immuno-modulatory activity |
ATE490788T1 (de) | 2003-04-25 | 2010-12-15 | Gilead Sciences Inc | Antivirale phosphonate analoge |
WO2005009345A2 (en) | 2003-06-13 | 2005-02-03 | Kosan Biosciences, Inc. | 2-desmethyl ansamycin compounds |
WO2005044308A1 (en) | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Phosphonate analogs of antimetabolites |
WO2005044279A1 (en) | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Purine nucleoside phosphonate conjugates |
EP1678322A2 (de) | 2003-10-24 | 2006-07-12 | Gilead Sciences, Inc. | Verfahren und zusammensetzungen zur identifizierung therapeutischer verbindungen |
US6855705B1 (en) | 2003-11-12 | 2005-02-15 | Kosan Biosciences, Inc. | 11-O-methylgeldanamycin compounds |
US6875863B1 (en) | 2003-11-12 | 2005-04-05 | Kosan Biosciences, Inc. | 11-O-methylgeldanamycin compounds |
WO2005056531A1 (en) * | 2003-11-12 | 2005-06-23 | Kosan Biosciences, Inc. | 11-o-methylgeldanamycin compounds |
US6887993B1 (en) | 2003-11-12 | 2005-05-03 | Kosan Biosciences, Inc. | 11-O-methylgeldanamycin compounds |
JP2007515495A (ja) | 2003-12-22 | 2007-06-14 | ギリアード サイエンシーズ, インコーポレイテッド | 4’−置換カルボビル誘導体およびアバカビル誘導体ならびにhivおよびhcv抗ウイルス活性を有する関連化合物 |
CA2547343C (en) | 2003-12-23 | 2013-05-14 | Infinity Pharmaceuticals, Inc. | Analogs of benzoquinone-containing ansamycins for the treatment of cancer |
US20060019941A1 (en) * | 2003-12-23 | 2006-01-26 | Infinity Pharmaceuticals, Inc. | Analogs of benzoquinone-containing ansamycins and methods of use thereof |
DE10361944A1 (de) * | 2003-12-31 | 2005-07-28 | Viromics Gmbh | Mittel zur Hemmung der Virusreplikation durch Regulation der Proteinfaltung |
WO2005095347A1 (en) * | 2004-03-26 | 2005-10-13 | Van Andel Research Institute | Geldanamycin and derivatives inhibit cancer invasion and identify novel targets |
US7259156B2 (en) | 2004-05-20 | 2007-08-21 | Kosan Biosciences Incorporated | Geldanamycin compounds and method of use |
EP1778251B1 (de) | 2004-07-27 | 2011-04-13 | Gilead Sciences, Inc. | Nukleosid phosphonat konjugate als anti hiv mittel |
US20080171687A1 (en) * | 2004-09-16 | 2008-07-17 | Abraxis Bioscience, Inc. | Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs |
US20060067953A1 (en) * | 2004-09-29 | 2006-03-30 | Conforma Therapeutics Corporation | Oral pharmaceutical formulations and methods for producing and using same |
CN101072504A (zh) * | 2004-11-02 | 2007-11-14 | 康福玛医药公司 | 治疗慢性淋巴细胞性白血病的方法和组合物 |
WO2006098761A2 (en) | 2005-03-11 | 2006-09-21 | The Regents Of The University Of Colorado | Hsp90 inhibitors, methods of making and uses therefor |
WO2007002093A2 (en) * | 2005-06-21 | 2007-01-04 | Infinity Discovery, Inc. | Ansamycin formulations and methods of use thereof |
AU2006263111A1 (en) * | 2005-06-29 | 2007-01-04 | Kyowa Hakko Kirin Co., Ltd. | Benzenoid ansamycin derivative |
AU2006320435A1 (en) * | 2005-12-01 | 2007-06-07 | Conforma Therapeutics Corporation | Compositions containing ansamycin |
AR061185A1 (es) | 2006-05-26 | 2008-08-13 | Chugai Pharmaceutical Co Ltd | Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas. |
ES2389740T3 (es) | 2006-11-09 | 2012-10-31 | Bristol-Myers Squibb Company | Nuevos compuestos y procedimientos para su producción |
PE20081506A1 (es) | 2006-12-12 | 2008-12-09 | Infinity Discovery Inc | Formulaciones de ansamicina |
CL2008000629A1 (es) * | 2007-03-01 | 2008-08-29 | Chugai Pharmaceutical Co Ltd | Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer. |
WO2008128063A1 (en) * | 2007-04-12 | 2008-10-23 | Infinity Discovery, Inc. | Hydroquinone ansamycin formulations |
EP2190291B1 (de) | 2007-08-23 | 2015-10-14 | The Regents of The University of Colorado, A Body Corporate | Hsp90-hemmer mit modifizierter toxizität |
KR20100074177A (ko) | 2007-09-10 | 2010-07-01 | 유니버시티 오브 매사추세츠 | 미토콘드리아-표적화된 항-종양 물질 |
US20090186039A1 (en) * | 2008-01-18 | 2009-07-23 | Jang Sung-Key | Novel use of grp 94 in virus infection |
CN101220068B (zh) * | 2008-01-18 | 2012-06-13 | 中国医学科学院医药生物技术研究所 | 一组格尔德霉素衍生物及其制备方法 |
AU2009268681B2 (en) | 2008-07-08 | 2014-10-02 | Gilead Sciences, Inc. | Salts of HIV inhibitor compounds |
WO2010045442A1 (en) * | 2008-10-15 | 2010-04-22 | Infinity Discovery, Inc. | Ansamycin hydroquinone compositions |
US20110201587A1 (en) * | 2010-02-16 | 2011-08-18 | Bio Holding, Inc. | Hsp90 inhibitors and methods of use |
US9603829B2 (en) | 2011-11-14 | 2017-03-28 | The Regents Of The University Of Colorado, A Body Corporate | HSP90 inhibitors with modified toxicity |
EP3960740B1 (de) | 2017-08-01 | 2023-11-15 | Gilead Sciences, Inc. | Kristalline formen von ethyl((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluor-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninat (gs-9131) vanillate zur behandlung von virusinfektionen |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3595955A (en) | 1969-03-26 | 1971-07-27 | Upjohn Co | Geldanamycin and process for producing same |
US4261989A (en) * | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
US4699877A (en) | 1982-11-04 | 1987-10-13 | The Regents Of The University Of California | Methods and compositions for detecting human tumors |
US4918162A (en) | 1986-05-06 | 1990-04-17 | The Regents Of The University Of California | Assays and antibodies for N-MYC proteins |
US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5627165A (en) | 1990-06-13 | 1997-05-06 | Drug Innovation & Design, Inc. | Phosphorous prodrugs and therapeutic delivery systems using same |
HU9401936D0 (en) | 1992-01-06 | 1994-09-28 | Pfizer | Process and uses for 4,5-diohydrogeldanamycin and its hydroquinone |
US5387584A (en) | 1993-04-07 | 1995-02-07 | Pfizer Inc. | Bicyclic ansamycins |
EP0706516A1 (de) | 1993-06-29 | 1996-04-17 | Pfizer Inc. | Ansamycin-derivate als antionkogene und antikrebsmittel |
US5932566A (en) * | 1994-06-16 | 1999-08-03 | Pfizer Inc. | Ansamycin derivatives as antioncogene and anticancer agents |
US5846749A (en) | 1994-10-12 | 1998-12-08 | The Regents Of The University Of California | Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination |
BR9713661A (pt) | 1996-12-30 | 2000-10-24 | Battelle Memorial Institute | Formulação e método para o tratamento de neoplasmas por inalação |
ATE460423T1 (de) | 1997-05-14 | 2010-03-15 | Sloan Kettering Inst Cancer | Verfahren und zubereitungen zur zerstörung bestimmter proteine |
US5968921A (en) | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
AU3378599A (en) | 1998-04-03 | 1999-10-25 | University Of Pittsburgh | Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke |
US6174875B1 (en) | 1999-04-01 | 2001-01-16 | University Of Pittsburgh | Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke |
CA2429196A1 (en) | 2000-03-24 | 2001-10-04 | Duke University | Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto |
AU2001271567A1 (en) | 2000-06-29 | 2002-01-14 | Trustees Of Boston University | Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders |
CA2417495C (en) | 2000-07-28 | 2013-04-30 | Sloan-Kettering Institute For Cancer Research | Methods for treating cell proliferative disorders and viral infections |
KR20030065502A (ko) | 2000-11-02 | 2003-08-06 | 슬로안-케테링인스티튜트퍼캔서리서치 | 에이치에스피90 저해제를 이용한 세포독성 제제의 효능을향상시키는 방법 |
AU2002228771B2 (en) | 2000-11-02 | 2007-10-25 | Sloan-Kettering Institute For Cancer Research | Small molecule compositions for binding to HSP90 |
CA2440809A1 (en) | 2001-03-01 | 2002-09-12 | Conforma Therapeutics Corp. | Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors |
JP2004529188A (ja) | 2001-05-23 | 2004-09-24 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 上昇に関連した癌の治療法 |
WO2003026571A2 (en) | 2001-09-24 | 2003-04-03 | Conforma Therapeutics Corporation | Process for preparing 17-allyl amino geldanamycin (17-aag) and other ansamycins |
AU2002343604C1 (en) | 2001-10-30 | 2009-09-17 | Conforma Therapeutics Corporation | Purine analogs having HSP90-inhibiting activity |
US7553979B2 (en) | 2001-11-09 | 2009-06-30 | Conforma Therapeutics Corporation | HSP90-inhibiting zearalanol compounds and methods of producing and using same |
CA2468202A1 (en) | 2001-12-12 | 2003-06-19 | Conforma Therapeutics Corporation | Assays and implements for determining and modulating hsp90 binding activity |
DE60327994D1 (de) | 2002-02-08 | 2009-07-30 | Conforma Therapeutics Corp | Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften |
TW200303363A (en) | 2002-02-25 | 2003-09-01 | Upjohn Co | Process to prepare and isolate geldanamycin |
-
2003
- 2003-02-10 DE DE60327994T patent/DE60327994D1/de not_active Expired - Lifetime
- 2003-02-10 AU AU2003217393A patent/AU2003217393B8/en not_active Ceased
- 2003-02-10 EP EP03713437A patent/EP1472230B1/de not_active Expired - Lifetime
- 2003-02-10 WO PCT/US2003/004283 patent/WO2003066005A2/en active Application Filing
- 2003-02-10 JP JP2003565431A patent/JP2005530689A/ja not_active Withdrawn
- 2003-02-10 AT AT03713437T patent/ATE433961T1/de not_active IP Right Cessation
- 2003-02-10 CA CA002474508A patent/CA2474508A1/en not_active Abandoned
- 2003-02-10 US US10/503,880 patent/US7465718B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU2003217393B8 (en) | 2009-06-25 |
EP1472230B1 (de) | 2009-06-17 |
WO2003066005A2 (en) | 2003-08-14 |
AU2003217393B2 (en) | 2009-02-26 |
WO2003066005A3 (en) | 2004-06-10 |
EP1472230A4 (de) | 2005-07-06 |
EP1472230A2 (de) | 2004-11-03 |
US7465718B2 (en) | 2008-12-16 |
US20050267122A1 (en) | 2005-12-01 |
JP2005530689A (ja) | 2005-10-13 |
AU2003217393A1 (en) | 2003-09-02 |
CA2474508A1 (en) | 2003-08-14 |
ATE433961T1 (de) | 2009-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE433961T1 (de) | Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften | |
CY1120257T1 (el) | ΠΥΡΡΟΛΟ[2,3b]ΠΥΡΙΔΙΝ-4-ΥΛΑΜΙΝΕΣ ΚΑΙ ΠΥΡΡΟΛΟ[2,3b]ΠΥΡΙΜΙΔΙΝ-4-ΥΛΑΜΙΝΕΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΩΝ JANUS | |
CY1108544T1 (el) | Παραγωγα πυραζολιου, συνθεσεις που περιεχουν τετοιες ενωσεις και μεθοδοι χρησης | |
CY1105247T1 (el) | Υποκατεστημενα παραγωγα c- κυκλοεξυλομεθυλαμινης | |
ATE478840T1 (de) | 3-aminoazetidinderivate enthaltende pharmazeutische zusammensetzungen, diese derivate und deren herstellung | |
CY1110225T1 (el) | Κυκλικοι αναστολεις πρωτεϊνικης τυροσινικης κινασης | |
BR0208338A (pt) | Derivados de piridina | |
EE200200357A (et) | Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid | |
DE60232660D1 (de) | Humane dr4-antikörper und deren anwendungen | |
CY1107773T1 (el) | Τυποποιησεις που περιεχουν εκτεïνασκιδινη και δισακχαριτη | |
ATE231872T1 (de) | Thiazolopyrimidinderivate | |
CO5660287A2 (es) | Derivados de tetrahidrocarbazol y su uso farmaceutico | |
BR0014352A (pt) | Cetoenóis espirocìclicos substituìdos por trifluormetila | |
ES2184149T3 (es) | Paclitaxeles 6-tio sustituidos. | |
CY1105225T1 (el) | Παραγωγα 5-β-σαπωγενινης και ψευδοσαπωγενινης και η χρηση τους στην αντιμετωπιση ανοιας | |
CY1105953T1 (el) | Συνθεσεις για απελευθερωση συνδυασμων φαρμακων | |
DK1654253T3 (da) | Substituerede 3-pyrrolidinindolderivater | |
UY27455A1 (es) | Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos. | |
ITMI20031570A1 (it) | Composizione per uso dietetico, farmaceutico o cosmetico | |
CY1107231T1 (el) | Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης | |
TR200100895T2 (tr) | Heterosiklik ikameli propanolamin türevleri, üretimi, ilaçları,kullanımı | |
ITMI20031396A1 (it) | Composizione per uso farmaceutico o dietetico o cosmetico dotata di attivita' antiossidante. | |
CY1111048T1 (el) | Ενωσεις που εμφανιζουν αντικαρκινικη δραστηριοτητα | |
ITRM20030363A0 (it) | Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse. | |
ATE497967T1 (de) | Interzelluläre kommunikation erleichternden verbindungen und deren medizinischen verwendungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |